Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
29 results
D1.33 - Patient-reported outcomes following beta-lactam antibiotic allergy delabeling work-up
D1.34 - Guideline adherence and safety of AI chatbots in allergology
D1.37 - Which Came First? Atopic Dermatitis or occupational Allergic Contact Dermatitis in a Surgeon with Tropomyosin-Driven IgE Cross-Reactivity
D1.38 - A Generalizable High-Throughput Nanobody Discovery Platform for Airborne Allergens
D1.39 - Oral Lichenoid Lesions Secondary to Contact Allergy to L-Carvone from Toothpaste: A Case Report
D1.40 - Independent Sensitization to poultry meat and tuna in a food allergic young girl
D1.41 - B cell responses to alarmins in type 2 inflammation
D1.42 - Unusual Delayed Hypersensitivity Reaction to Different Antibiotic Families
D1.44 - Primary care allergy and clinical immunology fellowship: A Delphi study of core competencies
D1.45 - Selective Anaphylaxis to Salmonids with Tolerance to Other Fish
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
D1.441 - A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download